Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.

For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31, 2012, the Company reported net income of $5.0 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30.0 million during 2011 were primarily responsible for the change in operating results year over year.

The Company's balance sheet at December 31, 2012 reflected total assets of $196.0 million, including cash, investments and receivables of $188.3 million compared with balances at December 31, 2011 of $138.4 million and $131.7 million, respectively.  During January 2012, the Company completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83.0 million.

"During 2012 we continued to perform to financial plan and were successful in moving our VMAT2 tardive dyskinesia program forward, as well as AbbVie advancing the elagolix endometriosis and uterine fibroids programs," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences. "Looking to 2013 we will have two Phase IIb readouts for our VMAT2 program, expect AbbVie to progress elagolix into Phase IIb in uterine fibroids, and we anticipate one additional program entering the clinic, resulting in a very productive year."

Revenues for the fourth quarter of 2012 were $21.9 million, compared to $11.1 million for the same period in 2011. The $10.8 million increase in revenue is primarily due to higher rev
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Topricin Pain Relief and ... been listed among nationally recommended over-the-counter (OTC) health ... by "U.S. News" Health in collaboration with "Pharmacy ... “No. 1 Pharmacists Recommended designation” in the “Topical ... brands, and is the only homeopathic formula to ...
(Date:5/17/2013)... Photographers know the ... see which branch a bird is sitting on, but spotting ... lens for high-magnification images requires considerable skill. It is a ... the active biomolecules of cells. , Olga Schubert, a doctoral ... her colleagues have now come up with a search aid. ...
(Date:5/17/2013)... 2013 New interactive learning ... thought leaders of the medical device industry at ... and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These all-new ... professionals practical presentations and implementable solutions on the ...
(Date:5/17/2013)... MIAMI , May 17, 2013  Insero Health, ... medical needs in epilepsy and related neurological disorders, is ... of its lead compound INS001 in patients with drug-resistant ... Drug and Device Trials (AED) Xll meeting by Dr. ... epileptologist and Chairman of Insero,s Scientific Advisory Board.  In ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... rise 3% over Fiscal 2006 to $27.5 million - ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Sept. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... recent announcements of the first shipment and commercial usage ...
... Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ) will be ... City on Thursday, October 4, 2007,from 12:00 p.m. - ... at Times,Square, on 270 West 43rd Street. The luncheon ... Ph.D., Chairman, President and,Chief Executive Officer and Gordon Brandt, ...
... is pleased to announce that the majority shares in ... Tampa,FL. (http://www.healthedgepartners.com ). Paul Guilbaud, ABT President ... exciting development of ABT. The acquisition allows us to ... necessary infrastructure for our,world- wide sales expansion and allow ...
Cached Biology Technology:Bioniche Reports Fiscal 2007 Year-End Results 2Bioniche Reports Fiscal 2007 Year-End Results 3Bioniche Reports Fiscal 2007 Year-End Results 4Bioniche Reports Fiscal 2007 Year-End Results 5Bioniche Reports Fiscal 2007 Year-End Results 6Bioniche Reports Fiscal 2007 Year-End Results 7Bioniche Reports Fiscal 2007 Year-End Results 8Bioniche Reports Fiscal 2007 Year-End Results 9Bioniche Reports Fiscal 2007 Year-End Results 10Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL 2
(Date:5/16/2013)... lining the body,s blood vessels, is extremely resilient. ... this super-tenuous structure routinely withstands blood flow, hydrostatic ... unique and highly dynamic barrier that maintains the ... circulatory system. , It,s also extremely adaptable. In ... to enable immune cells to reach various ...
(Date:5/16/2013)... A scientist has discovered an ancient extinct creature with ... it in honour of his favourite movie star. ... Kooteninchela deppi (pronounced Koo-ten-ee-che-la depp-eye), which is a ... the actor Johnny Depp for his starring role as ... named Edward, an unfinished creation, who has scissors for ...
(Date:5/16/2013)... the world are meeting next week in Toronto. ... the latest in research findings about the brain, ... the disorders that affect them., "Canada is a ... showcase the best of neuroscience research done here ... of the Canadian Association for Neuroscience. He also ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Actor Johnny Depp immortalized in ancient fossil find 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... for Biological Studies show that the only human gene ... is, in fact, riskier than realized. , The ... in the Laboratory of Genetics, discovered that the healthy ... cancer development. Their findings appear in this week's issue ...
... virus H5N1, derived from horses, prevent mice infected with ... study published today in the open access journal Respiratory ... 100 µg of horse anti-serum effectively protects infected mice. ... could potentially be used to prevent death from H5N1 ...
... Marine scientists have discovered that the deepest oceans of the ... a paper published today, an international team of researchers, led ... to colonise at depths greater than 3,000 metres. , Sharks ... that as man explores deeper into the abyss and beyond ...
Cached Biology News:Mouse study reveals human X-SCID gene therapy poses substantial cancer risk 2Mouse study reveals human X-SCID gene therapy poses substantial cancer risk 3Oceans are 70 percent shark free 2
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for PCNA in cells and tissues...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Biology Products: